You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

69 search results for: disease control

Current Treatment Options are not Effective for Achieving Full <b>Disease</b> <b>Control</b> in All Patients with CSU

expert video

Current Treatment Options are not Effective for Achieving Full Disease Control in All Patients with CSU

1 min

Dermatology

Dr. Casale presents the data on the use of antihistamines at licensed doses, indicating that only a minority achieve disease control.

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

20 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

IRS-ISIAN 2024 | Guideline Definitions of <b>Control</b> in CRSwNP

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

Impact of Advanced Systemic Therapies on <b>Disease</b> <b>Control</b> in AD

expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

Dermatology

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

Describing <b>Disease</b> <b>Control</b> in PN

expert video

Describing Disease Control in PN

5 min

Dermatology

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.

Infographic

Importance of Monitoring and Maintenance in EoE

5 min

Gastroenterology

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL

Most Children With Atopic Dermatitis Have Un<b>control</b>led <b>Disease</b>

expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

1 min

Dermatology

Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.

What do we mean by <b>disease</b> <b>control</b> in AD?

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

On-Treatment Asthma Remission: Moving Beyond <b>Control</b>

interactivity

On-Treatment Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma

Comparative Efficacy of Biologics for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

expert video

Guideline and Patient Management in CSU

4 min

Dermatology

Drs. Maurer and Ensina discuss cutting-edge strategies for managing CSU in this insightful interview.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SpainChange country/region